ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
S&P ASX 20 Index

S&P ASX 20 Index (XTL)

4,546.10
-68.30
(-1.48%)
Closed December 21 12:00AM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
4,546.10
Price Change
-68.30
Change %
-1.48%
Name
S&P ASX 20 Index
Symbol
XTL
4,536.40 Day's Range 4,614.40
4,165.30 52 Week Range 4,787.20
Bid
0.00
Ask
0.00
Open
4,614.40
High
4,614.40
Low
4,536.40
Close
4,546.10
Previous Close
4,614.40
Market
Australian Stock Exchange
Type
Index

XTL Latest News

XTL Biopharmaceuticals Provides Update on Potential Strategic Alternatives

VALLEY COTTAGE, N.Y., Jan. 28 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLBNASDAQ:TASE:NASDAQ:XTL) today announced an update to its December 8, 2008 press release regarding...

XTLbio Announces Grant of hMAb Patent

XTLbio Announces Grant of Human Monoclonal Antibody Patent Patent Covers Antibodies Directed Against Hepatitis B Virus Surface Antigen Rehovot, Israel 26 January 2004 - XTL Biopharmaceuticals...

XTLbio appoints Stockbroker and Financial Adviser

XTLbio appoints Stockbroker and Financial Adviser Rehovot, 20 January 2004 - The Board of XTL Biopharmaceuticals Ltd ("XTLbio" or the "Company") is pleased to announce the appointment of Code...

XTLbio announces appointment of Non-Executive Director

XTLbio announces appointment of Non-Executive Director Rehovot, 12 January 2004 - XTL Biopharmaceuticals Ltd. (LSE:XTL) is pleased to announce the appointment of Peter Stalker, III, as a...

Business Update

RNS Number:2908T XTL Biopharmaceuticals Limited 16 December 2003 XTLbio R&D and Business Development Update Rehovot, Israel, 16 December 2003 - XTL Biopharmaceuticals Ltd (XTLbio) today...

XTLbio R&D and Business Development Update

XTLbio R&D and Business Development Update Rehovot, Israel, 16 December 2003 - XTL Biopharmaceuticals Ltd (XTLbio) today announces an update on recent clinical progress and corporate developments...

XTLbio Highlights Presence at The Liver Meeting

XTLbio Highlights Presence at The Liver Meeting HepeX Programs at 54th Annual AASLD include Poster Presentations, Oral Presentation and Exhibitors Booth Rehovot, Israel, 28 October 2003: XTL...

Directorate Change

XTLbio announces appointment of Non-Executive Director Rehovot, Israel, 20 October 2003: XTL Biopharmaceuticals Ltd. (LSE:XTL) is pleased to announce the appointment of Dr. Hadar Ron as a...

Holding(s) in Company

NOTIFICATION OF MAJOR INTERESTS IN SHARES 1) Name of company XTL Biopharmaceuticals Limited 2) Name of shareholder having a major interest Perpetual Income & Growth Investment Trust plc 3) Please...

XTLbio ACQUIRES RIGHTS FROM STANFORD UNIVERSITY

XTLbio ACQUIRES BROAD RIGHTS FROM STANFORD UNIVERSITY TO ANTIBODIES DIRECTED AGAINST HEPATITIS C VIRUS (HCV) Exclusive license enhances XTLbio's HepeX-C program in clinical development Rehovot...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-162.9-3.45933319176470947304536.400IX
4-134.8-2.879788074944680.94787.24536.400IX
12-43.2-0.9413200270194589.34787.24536.400IX
261262.85061423954420.14787.24335.500IX
52318.57.533825338254227.64787.24165.300IX
156553.513.86314682163992.64787.23613.900IX
260778.220.65341436873767.94787.22519.300IX
Indices
Commodities
Forex
US5005,921.2060.201.03%
US3042,975.00522.001.23%
US1002,968.4084.502.93%
DJI42,840.26498.021.18%
SP5005,930.8563.771.09%
COMPX19,572.60199.831.03%
DXY107.5260.000.00%